This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sun, L.-Q. Articles by Coucke, P. A. Search for Related Content PubMed PubMed Citation Articles by Sun, L.-Q. Articles by Coucke, P. A.

Antitumor and Radiosensitizing Effects of (E)-2'-Deoxy-2'-(fluoromethylene) Cytidine, a Novel Inhibitor of Ribonucleoside Diphosphate Reductase, on Human Colon Carcinoma Xenografts in Nude Mice

Laboratory of Radiobiology, Department of Radiation Oncology [L-Q. S., Y-X. L., R-O. M., P. A. C.], and Department of Pathology [L. G.], University Hospital of Lausanne (CHUV), CH-1011 Lausanne, Switzerland

Antitumor and radiosensitizing effects of (E)-2'-deoxy-2'-(fluoromethylene) cytidine (FMdC), a novel inhibitor of ribonucleotide reductase, were evaluated on nude mice bearing s.c. xenografts and liver metastases of a human colon carcinoma. FMdC given once daily or twice weekly has a dose-dependent antitumor effect. The maximum tolerated dose in the mice was reached with 10 mg/kg applied daily over 12 days. Twice weekly administration of FMdC reduced its toxicity but lowered the antitumor effect. Treatment of preestablished liver micrometastases obtained via intrasplenic injection of tumor cells, with 5 or 10 mg/kg FMdC, significantly prolonged the survival of the mice as compared to controls (P < 0.025 and P < 0.001, respectively). Ten mg/kg resulted in longer survival than 5 mg/kg FMdC (P < 0.05). Radiotherapy alone of s.c. xenografts (10 fractions over 12 days) yielded the radiation dose required to produce local tumor control in 50% of the treated mice (TCD₅₀) of 43.0 Gy. When combined with FMdC, TCD₅₀ was reduced to 22.5 and 19.0 Gy at doses of 5 and 10 mg/kg given i.p. 1 h before each irradiation, respectively. The corresponding enhancement ratios were 1.91 and 2.43, respectively. FMdC produced moderate and reversible myelosuppression. When 5 mg/kg FMdC was combined with irradiation, there was no increased skin or hematological toxicity as compared to radiotherapy or FMdC alone. At the 10 mg/kg level, however, lower leukocyte counts were observed. These results show that FMdC appears to be a potent anticancer drug and radiosensitizer.

¹ To whom requests for reprints should be addressed.

Received 4/21/97. Accepted 7/14/97.

This article has been cited by other articles:

				G. I. Rodriguez, R. E. Jones, E. K. Orenberg, M. L. Stoltz, and D. J. Brooks Phase I Clinical Trials of Tezacitabine [(E)-2'-Deoxy-2'-(fluoromethylene)cytidine] in Patients with Refractory Solid Tumors Clin. Cancer Res., September 1, 2002; 8(9): 2828 - 2834. [Abstract] [Full Text] [PDF]

				Y. Zhou, G. Achanta, H. Pelicano, V. Gandhi, W. Plunkett, and P. Huang Action of (E)-2'-Deoxy-2'-(fluoromethylene)cytidine on DNA Metabolism: Incorporation, Excision, and Cellular Response Mol. Pharmacol., January 1, 2002; 61(1): 222 - 229. [Abstract] [Full Text] [PDF]

				P. A. Coucke, L. A. Decosterd, Y.-X. Li, E. Cottin, X. Chen, L.-Q. Sun, S. Stern, N. Paschoud, and J. Denekamp The Ribonucleoside Diphosphate Reductase Inhibitor (E)-2'-Deoxy-(fluoromethylene)cytidine as a Cytotoxic Radiosensitizer in Vitro Cancer Res., October 1, 1999; 59(20): 5219 - 5226. [Abstract] [Full Text] [PDF]